In a contemporary cohort, our data show an absolute survival advantage of 10% at 2 years with GO-containing induction therapy and acceptable toxicity, thereby supporting the integration of GO into treatment algorithms for patients with CBF-AML. Here, CEBPZ is linked to acute myeloid leukemia.